Trial Profile
Phase II Pilot Clinical Trial of Pazopanib in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) or at Initial Diagnosis When no Intensive Treatment is Possible
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms PazoAML; PAZOPANIB-AML
- 01 Jun 2019 Primary endpoint (Reduction of BM microvessel density on day 28) has not been met as per results published in the Annals of Hematology.
- 01 Jun 2019 Results assessing safety and efficacy of pazopanib in patients with relpased or refractory or newly diagnosed acute myeloid leukemia, published in the Annals of Hematology.
- 18 May 2016 Status changed from active, no longer recruiting to completed.